Medical Device and Healthcare Industry Update — April 17, 2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Osstem Implant has successfully secured EU Medical Device Regulation (MDR) certification for its 'K3' and 'K5' dental chairs, paving the way for further expansion into the European market. Meanwhile, GC Wellbeing and Alteogen Biologics have teamed up for the domestic distribution of the recombinant hyaluronidase 'Tergase,' signaling a shift in local market dynamics. Notably, software-based medical devices are becoming dominant in clinical trials, now accounting for half of all ongoing studies.
Medical Device and Healthcare Industry Update — April 17, 2026
Medical Device Technology & Industry News
Osstem Implant Obtains EU MDR Certification for Dental Chairs
Osstem Implant has received EU Medical Device Regulation (MDR) certification for its 'K3' and 'K5' dental chairs. This achievement follows their previous success with implants, marking a significant step in navigating the strict European regulatory landscape for dental equipment. The industry is now watching to see if this will serve as a catalyst for broader international sales.
GC Wellbeing and Alteogen Biologics Sign 'Tergase' Distribution Deal
GC Wellbeing (CEO Sang-hyun Kim) announced a joint sales agreement with Alteogen Biologics (CEO Hee-jung Jee) for the human-derived recombinant hyaluronidase 'Tergase' on April 16. The partnership aims to aggressively target the local market, raising expectations for enhanced product competitiveness within the healthcare sector.
New Advisory Body Formed for Hanmi Pharmaceutical’s Obesity Drug
A major talking point in the pharmaceutical and biotech sector this third week of April was the launch of an official council to discuss the commercialization of Hanmi Pharmaceutical’s obesity drug, which is expected to receive market approval this year. As talks surrounding the launch solidify, interest in the broader obesity treatment ecosystem is growing.
Policy & Regulatory Updates
MFDS Launches Tech Support Program for International Quality Standards
The Ministry of Food and Drug Safety (MFDS) is inviting manufacturers to apply for its 2026 technical support program, which helps companies align with international medical device quality standards. Applications are open until the 21st, with the goal of strengthening the quality management capabilities of local manufacturers.
National Bio-Innovation Committee Targets Regulatory Reform for AI Medical Devices
Prime Minister Kim Min-seok, chair of the National Bio-Innovation Committee, has unveiled a strategy featuring 24 tasks across four key areas. The plan includes streamlining regulations for AI-based medical devices and rare disease treatments, aiming to accelerate the market entry of new drugs and medical technologies.
FSS to Overhaul Disclosure Standards for Biotech Firms
The Financial Supervisory Service (FSS) launched a consultative body on the 10th to overhaul how pharmaceutical and biotech companies disclose information. The initiative aims to standardize terminology and reporting structures to resolve confusion regarding clinical trial results, ultimately increasing transparency for investors.
Clinical Research & Healthcare Trends
Software-Based Devices Now Account for Half of Local Clinical Trials
Software-based medical devices—ranging from diagnostic algorithms and rehab software to digital therapeutics (DTx)—are becoming the primary focus of clinical research. With these technologies now accounting for 50% of all clinical trials, it is clear that the development landscape is undergoing a massive shift.
Clinical Efficacy Reported for 'PTING' Microwave Aesthetic Device
At the 49th Spring Academic Conference of the Korean Academy of Aesthetic Medicine in March, Dr. Yang-Hyun Jo presented clinical data on 'PTING,' a microwave-based aesthetic device. The presentation highlighted the precision-targeting capabilities of the technology in a formal academic setting.
AI Expansion in Healthcare: From Efficiency to Autonomous Surgery
Discussions at the Korea Healthcare Congress (KHC 2026) centered on the widespread adoption of AI. Experts noted that AI is moving beyond simple operational efficiency and into complex domains like remote and autonomous surgery, as shared by speakers like Chang-heon Oh from Daewoong Pharmaceutical.
Summary & Outlook
The industry saw a mix of regulatory milestones, strategic partnerships, and policy updates this week.
Osstem Implant’s EU MDR success highlights the push for international certification, while the partnership between GC Wellbeing and Alteogen Biologics demonstrates the growing trend of collaborative market entry. On the policy front, the National Bio-Innovation Committee’s focus on AI regulation and the MFDS’s quality support program indicate strong institutional support for digital and globalized manufacturing.
Finally, the shift toward software-heavy clinical trials and the move toward AI-driven autonomous surgery underscore the rapid digital transformation defining the future of the healthcare industry.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
